3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
60
Neoplasm Metastasis
6
Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Ovarian Neoplasms
2
Neuroblastoma
2
Neoplasms by Site
2
Melanoma
2
Hereditary Sensory and Autonomic Neuropathies
2
Glioma
2
Glioblastoma
2
Carcinoma, Ovarian Epithelial
2
Breast Diseases
2
Anatomic Stage II Breast Cancer AJCC v8
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Sarcoma
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Meningioma
1
Medulloblastoma
1
Interventions
pembrolizumab
34
Cisplatin
29
Paclitaxel
15
Brachytherapy
15
Radiotherapy
14
Carboplatin
14
Bevacizumab
14
Blood Specimen Collection
13
Specimen Handling
12
Magnetic Resonance Spectroscopy
11
Colposcopy
11
Nivolumab
10
Drug Therapy
10
atezolizumab
8
Human Papillomavirus DNA Tests
8
Gemcitabine
8
lenvatinib
7
Radiation
6
Platinum
6
Biopsy
6
toripalimab
5
cemiplimab
5
Surveys and Questionnaires
5
Standard of Care
5
Radiotherapy, Intensity-Modulated
5
Practice Guidelines as Topic
5
Patient Navigation
5
Fulvestrant
5
Fluorodeoxyglucose F18
5
zimberelimab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
ribociclib
×
1 year
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled